Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Cash from Operations (Quarterly): -19.80M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -19.80M |
| December 31, 2023 | -16.12M |
| September 30, 2023 | -17.95M |
| June 30, 2023 | -18.77M |
| March 31, 2023 | -20.18M |
| December 31, 2022 | 14.71M |
| September 30, 2022 | -28.81M |
| June 30, 2022 | -33.35M |
| March 31, 2022 | -40.94M |
| Date | Value |
|---|---|
| December 31, 2021 | -40.26M |
| September 30, 2021 | -31.93M |
| June 30, 2021 | -22.82M |
| March 31, 2021 | -22.04M |
| December 31, 2020 | -19.85M |
| September 30, 2020 | -6.716M |
| June 30, 2020 | -2.466M |
| March 31, 2020 | -1.699M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-40.94M
Minimum
Mar 2022
14.71M
Maximum
Dec 2022
-19.35M
Average
-19.85M
Median
Dec 2020
Cash from Operations (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | -10.38M |
| Lifecore Biomedical Inc | -17.29M |
| Relmada Therapeutics Inc | -13.04M |
| ACADIA Pharmaceuticals Inc | 29.08M |
| Cyclacel Pharmaceuticals Inc | -3.91M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.14M |
| Cash from Financing (Quarterly) | -0.022M |
| Free Cash Flow | -76.24M |
| Free Cash Flow Per Share (Quarterly) | -0.0862 |
| Free Cash Flow to Equity (Quarterly) | -19.94M |
| Free Cash Flow Yield | -16.23% |